Cardiol Therapeutics Inc.
CRDL
$1.41
$0.032.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.90% | -45.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.70% | -31.17% | |||
| Operating Income | 17.70% | 31.17% | |||
| Income Before Tax | 1.16% | 37.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.16% | 37.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.16% | 37.40% | |||
| EBIT | 17.70% | 31.17% | |||
| EBITDA | 17.52% | 31.21% | |||
| EPS Basic | 3.85% | 45.58% | |||
| Normalized Basic EPS | 3.74% | 45.63% | |||
| EPS Diluted | 3.85% | 45.58% | |||
| Normalized Diluted EPS | 3.74% | 45.63% | |||
| Average Basic Shares Outstanding | 2.74% | 15.13% | |||
| Average Diluted Shares Outstanding | 2.74% | 15.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||